Written Question·Department of Health and Social Care·UIN 429

Polycystic Ovary Syndrome: Semaglutide

Tabled: 17 July 2024

Answered: 29 July 2024

Question

Jess Asato

To ask the Secretary of State for Health and Social Care, whether his Department has made an assessment of the geographic disparities in the prescription of semiglutides for patients with polycystic ovary syndrome.

Answer

Karin Smyth

While semaglutide is not licensed as a treatment option for polycystic ovary syndrome (PCOS), clinicians can prescribe medicines outside their licensed indication, known as off-label prescribing, where they consider it to be the best treatment option for ...

ⓘ

This is an extract from the Parliament API. Search the full answer on Parliament.uk (UIN 429) →